The two essential requirements for pathologic specimens in the era of personalized therapies for non-small cell lung carcinoma (NSCLC) are accurate subtyping as adenocarcinoma (ADC) versus squamous cell carcinoma (SqCC) and suitability for EGFR molecular testing, as well as for testing of other oncogenes such as EML4-ALK and KRAS. Actually, the value of EGFR expressed in patients with NSCLC in predicting a benefit in terms of survival from treatment with an epidermal growth factor receptor targeted therapy is still in debate, while there is a convincing evidence on the predictive role of the EGFR mutational status with regard to the response to tyrosine kinase inhibitors (TKIs).This is a literature overview on the state-of-the-art of EGFR oncogenic mutation in NSCLC. It is designed to highlight the preclinical rationale driving the molecular footprint assessment, the progressive development of a specific pharmacological treatment and the best method to identify those NSCLC who would most likely benefit from treatment with EGFR-targeted therapy. This is supported by the belief that a rationale for the prioritization of specific regimens based on patient-tailored therapy could be closer than commonly expected.

Antonicelli, A., Cafarotti, S., Indini, A., Galli, A., Russo, A., Cesario, A., Lococo, F., Russo, P., Mainini, A., Bonifati, L., Nosotti, M., Santabrogio, L., Margaritora, S., Granone, P., Dutly, A., EGFR-targeted therapy for non-small cell lung cancer: focus on EGFR oncogenic mutation., <<INTERNATIONAL JOURNAL OF MEDICAL SCIENCES>>, 2013; (Ottobre): 320-330. [doi:10.7150/ijms.4609] [http://hdl.handle.net/10807/52994]

EGFR-targeted therapy for non-small cell lung cancer: focus on EGFR oncogenic mutation.

Cafarotti, Stefano;Cesario, Alfredo;Lococo, Filippo;Margaritora, Stefano;Granone, Pierluigi;
2013

Abstract

The two essential requirements for pathologic specimens in the era of personalized therapies for non-small cell lung carcinoma (NSCLC) are accurate subtyping as adenocarcinoma (ADC) versus squamous cell carcinoma (SqCC) and suitability for EGFR molecular testing, as well as for testing of other oncogenes such as EML4-ALK and KRAS. Actually, the value of EGFR expressed in patients with NSCLC in predicting a benefit in terms of survival from treatment with an epidermal growth factor receptor targeted therapy is still in debate, while there is a convincing evidence on the predictive role of the EGFR mutational status with regard to the response to tyrosine kinase inhibitors (TKIs).This is a literature overview on the state-of-the-art of EGFR oncogenic mutation in NSCLC. It is designed to highlight the preclinical rationale driving the molecular footprint assessment, the progressive development of a specific pharmacological treatment and the best method to identify those NSCLC who would most likely benefit from treatment with EGFR-targeted therapy. This is supported by the belief that a rationale for the prioritization of specific regimens based on patient-tailored therapy could be closer than commonly expected.
2013
Inglese
Antonicelli, A., Cafarotti, S., Indini, A., Galli, A., Russo, A., Cesario, A., Lococo, F., Russo, P., Mainini, A., Bonifati, L., Nosotti, M., Santabrogio, L., Margaritora, S., Granone, P., Dutly, A., EGFR-targeted therapy for non-small cell lung cancer: focus on EGFR oncogenic mutation., <<INTERNATIONAL JOURNAL OF MEDICAL SCIENCES>>, 2013; (Ottobre): 320-330. [doi:10.7150/ijms.4609] [http://hdl.handle.net/10807/52994]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/52994
Citazioni
  • ???jsp.display-item.citation.pmc??? 45
  • Scopus 106
  • ???jsp.display-item.citation.isi??? 95
social impact